7829.TWO Yoda Pharmaceuticals Inc.
- Market cap
- TWD 4.84B
- P/E
- -
- P/B
- 4.71x
- ROE
- -41.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 7829.TWO undervalued?
Graham numberThe Graham number of Yoda Pharmaceuticals Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Yoda Pharmaceuticals Inc. fundamental analysis
No fundamental analysis for Yoda Pharmaceuticals Inc. yet.
Yoda Pharmaceuticals Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Yoda Pharmaceuticals Inc.
Yoda Pharmaceuticals Inc., an AI-driven company, focuses on development of drugs targeting central nervous system disorders. The company's flagship drug, YA-101 is in Phase 2 clinical trial for the treatment of multiple system atrophy. It is also involved in the development pipeline includes drugs in the field of neurological and psychiatric disorders and cerebrovascular diseases, targeting conditions, such as schizophrenia, Alzheimer's disease, Parkinson"s disease, Autism, …
Full company profileYoda Pharmaceuticals Inc. financial statements
Yoda Pharmaceuticals Inc. annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | 0.00 | 0.00 | - | - |
| Operating Income | -45.1M | -89.9M | -222M | -392M |
| EBITDA | -43.1M | -84.5M | -191M | -405M |
| Net Income | -43.8M | -85.3M | -192M | -407M |
| EPS | -0.53 | -1.02 | -2.31 | -4.89 |
| Balance Sheet | ||||
| Total Assets | 30.4M | 359M | 644M | 1.02B |
| Total Liabilities | 12.6M | 22.8M | 18.4M | 33.5M |
| Shareholders' Equity | 17.8M | 336M | 626M | 984M |
| Cash & Short-term Investments | 19.2M | 34.8M | 569M | 325M |
| Cash Flow | ||||
| Operating Cash Flow | -44.2M | -76.7M | -187M | -353M |
| Capital Expenditure | 0.00 | 1.30M | 2.32M | 389K |
| Free Cash Flow | -44.2M | -78.0M | -190M | -354M |
| Ratios | ||||
| ROE | -246.9% | -25.4% | -30.7% | -41.4% |
| ROA | -144.4% | -23.8% | -29.8% | -40.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Yoda Pharmaceuticals Inc. dividends
Yoda Pharmaceuticals Inc. has not paid dividends in the last 4 fiscal years.
Who owns Yoda Pharmaceuticals Inc.
Ownership data of Yoda Pharmaceuticals Inc. is not available yet.
Yoda Pharmaceuticals Inc. company profile
- Company name
- Yoda Pharmaceuticals Inc.
- Ticker
- 7829.TWO
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Fiscal year end
- December
- Address
- The Grand Pavilion Commercial Centre, Grand Cayman, Cayman Islands, KY1- 1208
- Website
- yodapharma.com
About Yoda Pharmaceuticals Inc.
Yoda Pharmaceuticals Inc., an AI-driven company, focuses on development of drugs targeting central nervous system disorders. The company's flagship drug, YA-101 is in Phase 2 clinical trial for the treatment of multiple system atrophy. It is also involved in the development pipeline includes drugs in the field of neurological and psychiatric disorders and cerebrovascular diseases, targeting conditions, such as schizophrenia, Alzheimer's disease, Parkinson"s disease, Autism, ischemic stroke, and traumatic brain injury. Yoda Pharmaceuticals Inc. was incorporated in 2019 and is based in Grand Cayman, the Cayman Islands.
Yoda Pharmaceuticals Inc. management
3- Prof. Yufeng TsengFounder, CEO & Director
- Prof. Wen-Sung LaiFounder & Director
- Zhi Qiang ShenAccounting Supervisor